NVAX

Novavax Inc.

Price

$8.79

return (12m)

-7.67%

p/e

-5.32

p/bv

-6.90

DIVIDEND YIELD

0.00%

NVAX price

Novavax

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment NVAX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

9.40%

3 months

-2.12%

1 year

-7.67%

2 years

-36.76%

5 years

-96.50%

10 years

-93.92%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals NVAX

Valuation

P/E

-5.32

Sector -4.38

Industry -4.38

P/BV

-6.90

Sector 2.02

Industry 2.02

P/Revenue (PSR)

3.18

Sector -4.40

Industry -4.40

EV/EBITDA

-20.70

Sector -263.09

Industry -263.09

EV/EBIT

-19.33

Sector -702.90

Industry -702.90

P/EBITDA

-6.40

Sector -4.39

Industry -4.39

P/EBIT

-5.89

Sector -4.73

Industry -4.73

P/Total Assets

1.38

Sector 1.49

Industry 1.49

P/Net Current Assets

-3.51

Sector -11.70

Industry -11.70

P/Working Capital

2.99

Sector -3.19

Industry -3.19

EPS

-1.50

Sector -2.14

Industry -2.14

BVPS

-1.16

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

78.60%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-75.71%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-81.11%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-32.93%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-59.87%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.06

Sector 0.03

Industry 0.03

Profitability

ROE

129.90%

Sector -65.14%

Industry -65.14%

ROA

-25.92%

Sector -65.53%

Industry -65.53%

ROIC

-53.15%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

2.33

Sector 2.90

Industry 2.90

Net Debt / EBITDA

9.97

Sector -6.07

Industry -6.07

Net Debt / EBIT

9.30

Sector -8.26

Industry -8.26

Net Debt / Equity

2.24

Sector -1.07

Industry -1.07

Gross Debt / Equity

-1.53

Sector -0.05

Industry -0.05

Equity/Assets

-0.20

Sector 0.41

Industry 0.41

Liabilities/Assets

1.20

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

15.93%

Sector -

Industry -

5Y Earnings CAGR

-32.31%

Sector -

Industry -

Fundamentals NVAX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
NVAX Novavax Inc.	$8.79	-9.47%	0.00%	-5.32	-6.90	129.90%	-59.87%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NVAX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Novavax

Novavax Inc.

Average Investor10 user rating

4.0 (6 people)

United States

39 years

Founded: 1987

1995

Time since IPO - 31 years

791

Employees

Novavax Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.32 billion, with shareholders equity totaling $-190.71 million.

The company employs approximately 791 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Novavax Inc. reported $413.79 million in revenue, generating net income of $-247.73 million.

Key financial metrics include a P/E ratio of -5.32, a price-to-book (P/B) ratio of -6.90, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NVAX.

Market cap

$1.32 billion

Net worth

$-190.71 million

$-190,710,000.00

Assets

$955.58 million

$955,580,000.00

Total Shares Outstanding

165.00 million

165,000,000

Average Daily Trading Volume

$3.80 million

$3,801,548.00

Sector

Health Care

Industry

Biotechnology

NVAX

NVAX revenue and profits

Financial Results NVAX

DRAG THE FRAME TO SEE MORE DATA

NVAX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Novavax (NVAX) today?

A cotação de Novavax (NVAX) hoje está em US$ 8.79, com uma variação de -7.67% em relação ao último ano. A cotação de Novavax (NVAX) iniciou o ano negociando na casa dos US$ 6.72 e hoje está em US$ 8.79. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Novavax (NVAX) e dados de ações do Ibovespa e mercados internacionais.

Quando Novavax (NVAX) paga dividendos?

Novavax (NVAX) não distribuiu dividendos no último ano.

Is Novavax (NVAX) a good investment?

Atualmente, Novavax (NVAX) está cotada a US$ 8.79, com um P/L de -5.32, representando um desvio de -239% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -7.67 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -7.67%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Novavax (NVAX) stock?

Investir em ações de Novavax (NVAX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Novavax (NVAX) yield today?

A rentabilidade de Novavax (NVAX) foi de 9.40% no último mês, -7.67% no último ano e -96.50% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Novavax (NVAX) hoje, o investimento total seria de US$ 879.00, com base na cotação atual de US$ 8.79.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 811.58
Em 5 anos: US$ 30.77
Em 10 anos: US$ 53.44

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NVAX

Novavax Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NVAX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING NVAX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Novavax

Novavax Inc.

United States

39 years

1995

791

PROFIT X PRICE NVAX

Financial Results NVAX

NVAX cash flow

Asset, Revenue and Profit Growth - NVAX

NVAX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions